Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer

Zhong-Hui Li, Yin-Jie Ma, Zong-Hang Jia, Yue-Yan Weng, Ping Zhang, Shi-Jie Zhu, Fang Wang

BACKGROUND
Gemcitabine plus nab-paclitaxel (GA) is a commonly used first-line treatment regimen for metastatic pancreatic cancer, and many studies will add a novel targeted agent to this regimen for improving patient survival rate. However, the clinical effectiveness of GA is the most controversial issue.

AIM
To compare the efficacy and safety of GA regimen with a targeted agent and GA regimen.

METHODS
Up to 1 December 2021, the eligible randomized controlled trials (RCTs) relating to GA and GA with a targeted agent were searched on PubMed, EMBASE and Cochrane Library for eligible data. We screened out appropriate studies for overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and toxicity, which had been pooled and finally analyzed by using Stata version 15.1. In addition, we use Reference Citation Analysis (https://www.referencecitationanalysis.com/) to collect the latest related literature to improve the latest cutting-edge research results.

RESULTS
Seven RCTs involving 1544 patients (848 men and 696 women) were included.
There were no significant differences between GA with a targeted agent and GA in PFS [hazard ratio (HR): 1.18 95% confidence interval (CI): 0.91-1.53], OS (HR: 1.12 95% CI: 0.99-1.27), and ORR (HR: 0.96 95% CI: 0.71-1.29). There was no notable difference in the two groups in grade 3/4 toxicity (fatigue, anemia, vomiting and neutropenia), whereas the incidence of grade 3/4 diarrhea considerably increased in GA with a targeted drug.

**CONCLUSION**
Adding a novel targeted agent to the GA regimen did not improve survival rate of patients with metastatic pancreatic cancer.

**Key Words:** Metastatic pancreatic cancer; Gemcitabine; Nab-paclitaxel; Novel targeted agent; Survival

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Gemcitabine plus nab-paclitaxel (GA) is a commonly used first-line treatment regimen for metastatic pancreatic cancer, and many studies will add a novel targeted agent to this regimen to improve patient survival. However, the clinical effectiveness of GA is more controversial. We conducted a meta-analysis to compare the effectiveness and safety of GA combined with a targeted agent regimen and GA regimen.

**Citation:** Li ZH, Ma YJ, Jia ZH, Weng YY, Zhang P, Zhu SJ, Wang F. Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer. *World J Clin Cases* 2022; 10(27): 9703-9713
**URL:** https://www.wjgnet.com/2307-8960/full/v10/i27/9703.htm
**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i27.9703

**INTRODUCTION**
Pancreatic cancer is a highly malignant disease with annual incidence rates ranging from 0.5% to 1.0% [1]. One study predicted that by 2040, pancreatic cancer will be the second most common cause of cancer-related deaths in the United States [2]. The current treatment outcome of pancreatic cancer is still not ideal, and an important reason is the shortage of effective screening and diagnosing modalities, which causes most patients to be in locally advanced (30%-35%) or metastatic (50%-55%) stage when diagnosed. In addition, surgery is the only treatment modality to cure pancreatic cancer, but 80%-85% of pancreatic cancer patients have missed the opportunity for surgical resection when diagnosed [3]. Even if surgical treatment improves patient outcomes, the 5-year survival rate is still < 10% [4]. Currently, gemcitabine and albumin combined with paclitaxel or modified FOLFIRINOX (fluorouracil, calcium folinate, irinotecan and oxaliplatin) are the standard regimen for treating metastatic pancreatic cancer. According to the results of a phase III study on 861 patients with metastatic pancreatic cancer, Von Hoff et al [5] showed that gemcitabine plus nab-paclitaxel (GA) had a higher survival rate than single-agent gemcitabine [median survival 8.5 vs 6.7 mo; hazard ratio (HR): 0.72 95% confidence interval (CI): 0.62-0.83; P < 0.001].

The effectiveness of GA has been fully demonstrated by its widespread application in clinical practice and systematic analysis [6]. However, systematic analyses for effectiveness and safety in GA and FOLFIRINOX have shown that FOLFIRINOX has longer median overall survival (OS) and few differences in the overall risk of death and progression between FOLFIRINOX and GA [7]. Previous studies have compared gemcitabine with gemcitabine combinations, and meta-analysis has indicated that gemcitabine combined with targeted drugs does not improve OS and progression-free survival (PFS) in patients compared with gemcitabine alone [8]. Nevertheless, there has been no meta-analysis on whether GA regimens can improve effectiveness when combined with a targeted drug.

In clinical settings, targeted medicines with distinct modes of action, which could dramatically increase patients’ survival rate, play a critical role in cancer treatment. For instance, tarextumab, a novel anticancer stem cell antibody against Notch 2/3, has been demonstrated to decrease tumor stem cell growth, promote cell differentiation, disrupt tumor angiogenesis, and prevent tumor development [9]. Ibrutinib (pci-32765) is an irreversible inhibitor with high selectivity for Bruton tyrosine kinase (BTK) and high potency, and ibrutinib plus gemcitabine considerably improved survival rate in preclinical trials in pancreatic cancer [10-11]. A phase Ib study evaluated the safety and tolerability of pegvorhyaluronidase alfa (PEGPH 20) in combination with gemcitabine for advanced pancreatic cancer. PEGPH 20 was well tolerated, especially in patients with high hyaluronic acid [12]. It has also been found that adding istiratumab to GA improves chemotherapeutic activity [13]. Several studies have demonstrated
the high activity of hydroxymidroquine (HCQ) in pancreatic cancer models, and HCQ can improve the efficacy of chemotherapy especially for pancreatic cancer[14,15]. As a heat shock protein antagonist, only by binding to heat shock protein (Hsp) 27 RNA, apatorsen can function and will not be inhibited by downregulating the expression of heparanase[17,18]. In preliminary experiments, necuparanib has been found to inhibit tumor cell proliferation and invasion[19]. As a multitargeted heparan sulfate mimetic, it effectively avoids the drawbacks of heparin analogs that are prone to bleeding while retaining antiangiogenic effects[20,21], and it effectively participates in the antitumor immunomodulatory process[22]. In this study, we conducted a systematic collection and screening to evaluate the evidence and results of studies in relevant randomized controlled trials (RCTs).

MATERIALS AND METHODS

Literature Search
We performed a combined computerized and manual search using key words “pancreatic cancer”, “gemcitabine”, “nab-paclitaxel” and “metastatic”. We finished the final search on December 1, 2021. We only included papers written in English.

Inclusion and exclusion criteria
Inclusion criteria: (1) The study met the requirements of the RCTs’ experimental design; (2) The trial group was GA + a targeted drug and the control group was GA regimen or GA + placebo; (3) The study subjects were patients with advanced or metastatic pancreatic cancer diagnosed by pathology; and (4) Observed indicators included OS, PFS, objective response rate (ORR) and toxicity (fatigue, anemia, diarrhea, vomiting, neutropenia). Exclusion criteria: (1) Studies in patients with pancreatic cancer with significant comorbidities; (2) No complete observational index or single-arm pilot study; (3) Non-RCTs such as observational studies, reviews, case reports, and duplicate studies; and (4) Non-English papers.

Data extraction and quality evaluation
The titles and abstracts of all papers were evaluated by two investigators independently. If one of the investigators thought that the title and abstract of a particular paper had met the inclusion requirements, the final decision was made by the two investigators after reading the full text together. Any conflicts during the screening process would be resolved through discussion or a third party. The methodological quality of the included studies was determined using the Jadad scale[23]. We only included high-quality studies. All data including first author, year of publication, number of patients in the trial and control groups, treatment regimen observations (OS, PFS, ORR, and toxic response), and HR and 95% CI in the survival curves should be extracted from the included studies.

Data analysis
Statistical analysis of all data in this study was performed by Stata 15.1[24] with OS as the primary analysis; with PFS, ORR and adverse events as secondary analysis. Heterogeneity analysis before each trial was evaluated by Cochrane’s Q test and I² statistics, and a random-effects model was used if $P > 0.1$ or $I^2 > 50\%$ indicated heterogeneity between studies[25]. In contrast, we used a fixed-effects model. The studies were evaluated for publication bias by funnel plot and Egger test. $P < 0.05$ indicated a statistical difference.

RESULTS

Literature search and research characteristics
The steps for evaluating the inclusion and exclusion of studies in this system are shown in Figure 1. A total of 1886 relevant studies were screened out as ineligible after the titles and abstracts (included duplicates, single-arm studies, meta-analyses, reviews, case reports, retrospective studies, control groups and experimental groups) were read and did not meet the requirements. After reading the full text, we excluded 13 RCTs due to incomplete data and noncompliance of observation indicators, and we only included seven RCTs[26-32] in the final meta-analysis. The main characteristics of the seven included RCTs are listed in Table 1, with a total of 1544 patients, including 853 in the GA + a targeted drug group (tarextumab, ibrutinib, PEGPH 20, istiratumab, apatorsen, HCQ and necuparanib) and 691 in the GA + placebo group. All included trials met strict RCT trial design requirements and were of high quality (Jadad score > 3.) Seven studies provided data on OS, ORR, and grade 3/4 toxicity (fatigue, anemia, diarrhea, vomiting and neutropenia).
### Table 1 Characteristics of the eligible trials included in this systematic analysis of data on gemcitabine plus nab-paclitaxel + a targeted drug in metastatic pancreatic cancer

| Ref. | Median age | Gender (f/m) | Treatment            | Media OS (mo) | Median PFS (mo) | ORR [n (%)] |
|------|------------|--------------|----------------------|---------------|----------------|-------------|
| Kundranda et al.[26] | 60         | 16/27        | GA + istiratumab     | 8.7           | 3.6            | 17 (39.5%)  |
|             | 60         | 26/19        | GA + Placebo         | 11.7          | 7.1            | 22 (51.2%)  |
| Ko et al.[26]   | 66.5       | 29/37        | GA + apatorsen       | 5.3           | 2.7            | 12 (18%)    |
|             | 65.5       | 28/38        | GA + Placebo         | 6.9           | 3.8            | 12 (18%)    |
| O’Reilly et al.[30] | 65       | 33/29        | GA + necuparanib     | 10.71         | 5.52           | 14 (23%)    |
|             | 61         | 25/33        | GA + placebo         | 9.99          | 6.93           | 8 (14%)     |
| Karasic et al.[28] | 65        | 45/67        | GA + HCQ             | 11.1          | 5.7            | 21 (38.2%)  |
|             |            |              | GA + Placebo         | 12.1          | 6.4            | 12 (22.1%)  |
| Tempero et al.[32] | 64        | 97/144       | GA + Ibrutinib       | 9.69          | 5.32           | 62 (29%)    |
|             | 64         | 92/120       | GA + Placebo         | 10.78         | 6.03           | 90 (42%)    |
| Hu et al.[31]   | 66         | 39/50        | GA + Tarcevatumab    | 6.4           | 3.7            | 18 (20%)    |
|             | 66         | 34/54        | GA + Placebo         | 7.9           | 5.5            | 28 (32%)    |
| Van Cutsem et al.[27] | 63.8     | 147/180      | GA+PEGPH20           | 11.2          | 7.1            | 153 (47%)   |
|             | 62.3       | 85/80        | GA+Placebo           | 11.5          | 7.1            | 59 (36%)    |

OS: Overall survival; ORR: Objective response rates; f/m: Female/male; PFS: Progression-free survival; GA: Gemcitabine plus nab-paclitaxel; HCQ: Hydroxychloroquine.

**OS meta-analysis**

Median OS was provided for all seven RCTs, and HRs and 95% CIs were also available (Figure 2). OS $I^2 = 0.0\%$, $P = 0.083$ was not heterogeneous; therefore, we conducted a meta-analysis using a fixed-effects model. In accordance with the meta-analysis, there was no marked difference between GA + a targeted drug and GA + placebo for improving OS (HR: 1.13, 95% CI: 1.00-1.27, $P = 0.044$).

**PFS meta-analysis**

Six RCTs provided median PFS ($I^2 = 65.2\%$, $P = 0.013$), so we adopted a random-effects model (Figure 3). There was no marked difference between GA + a targeted drug and GA + placebo for improving PFS (HR: 1.16, 95% CI: 0.93-1.43, $P = 0.187$).

**ORR meta-analysis**

Seven RCTs provided ORRs ($I^2 = 46.2\%$, $P = 0.084$), thus we used a dichotomous fixed-effects model for analysis (Figure 4). There was no significant difference in ORR between GA + a targeted drug and GA + placebo (OR: 0.99, 95% CI: 0.80-1.21, $P = 0.892$).

**Tolerability**

Grade 3/4 toxicity, including fatigue, anemia, diarrhea, vomiting and neutropenia, was analyzed using a fixed-effects model (Table 2). There was no significant difference between the two groups in fatigue (OR: 1.07, 95% CI: 0.88-1.29, $P = 0.522$), anemia (OR: 0.97, 95% CI: 0.75-1.25, $P = 0.822$), vomiting (OR: 1.07, 95% CI: 0.84-1.36, $P = 0.595$), neutropenia (OR: 0.94, 95% CI: 0.73-1.22, $P = 0.657$), while there was a significant difference between the two groups for diarrhea (OR: 1.46, 95% CI: 1.17-1.83, $P = 0.001$).

**DISCUSSION**

Although GA regimen and modified FOLFIRINOX are the core first-line regimens for treating pancreatic cancer in clinical practice, we have to face the problem that the current regimens have limited effect in prolonging survival of pancreatic cancer patients, and we need to keep finding new therapeutic approaches for pancreatic cancer. Having demonstrated the effectiveness of some new targeted drugs for antitumor therapy, clinical trials have started to use GA in combination with targeted drugs for pancreatic cancer. However, GA regimens combined with targeted drugs did not bring better efficacy and did not significantly improve OS, PFS and ORR. Moreover, even combination regimens were less effective than GA regimens. There was no difference in grade 3/4 toxicity, including fatigue, anemia,
Table 2 Grade 3/4 toxicity with gemcitabine plus nab-paclitaxel + a targeted drug and gemcitabine plus nab-paclitaxel + placebo in metastatic pancreatic cancer

| Grade 3/4 toxicity | GA+ a targeted drug (n/N) | GA+ placebo (n/N) | Analysis model | OR (95%CI) | Z     | P     |
|--------------------|---------------------------|-------------------|----------------|-----------|-------|-------|
| Fatigue            | 367/777                   | 264/607           | Fixed effect   | 1.07 (0.88,1.29) | 0.642 | 0.522 |
| Anemia             | 166/452                   | 169/451           | Fixed effect   | 0.97 (0.75,1.25) | 0.225 | 0.822 |
| Vomiting           | 221/463                   | 360/497           | Fixed effect   | 1.07 (0.84,1.36) | 0.532 | 0.595 |
| Neutropenia        | 150/452                   | 158/451           | Fixed effect   | 0.94 (0.73,1.22) | 0.444 | 0.657 |
| Diarrhea           | 281/452                   | 194/451           | Fixed effect   | 1.46 (1.17,1.83) | 3.309 | < 0.01 |

GA: Gemcitabine plus nab-paclitaxel.

Vomiting and neutropenia, except for a significant increase in the incidence of diarrhea. Our results have important clinical implications, and more caution is needed for combining targeted agents on top of GA regimens in patients with metastatic pancreatic cancer.

The Notch pathway plays an important role in cancer treatment as anti-Notch 2/3 can reduce the incidence of tumors by downregulating Notch target genes. It has been found that anti-Notch 2/3 combined with chemotherapy is effective in a variety of cancers including pancreatic cancer, and it has been demonstrated that gemcitabine combined with anti-Notch 2/3 is more sensitive in the treatment of pancreatic cancer patients with a higher expression level of Notch3 gene. It has also been shown that GA in combination with anti-Notch 2/3 drugs has stronger antitumor effects than gemcitabine alone[9]. Although tarextumab showed high potential in preclinical studies, the three low, medium and high Notch subgroups did not show any discrepancies in PFS and OS in a randomized phase II study[31]. The above results may be due to patient variation in clinical studies, but also suggest that the specific

**DOI**: 10.12998/wjcc.v10.i27.9703  **Copyright** ©The Author(s) 2022.
role of the Notch pathway in pancreatic cancer is still controversial and needs further study. BTK may be involved in a variety of immune-related signaling pathways, and it may be a new antitumor target [33]. Studies have shown that the combination of ibrutinib and chemotherapy in the treatment of other cancers is beneficial in improving the effectiveness [34, 35]. However, ibrutinib did not improve PFS and OS in patients with metastatic pancreatic cancer in the phase III RESOLVE study [32], which was considered to be related to the addition of ibrutinib shortening the treatment duration of the original GA regimen. The main component of the extracellular matrix is hyaluronic acid (HA), increasing the interstitial gel fluid pressure within the tumor and reducing drug delivery to malignant cells. PEGPH 20 is a new drug that degrades HA to increase cytotoxic release, and PEGPH 20 inhibits tumor growth by degrading the HA-assembled extracellular skeleton to disintegrate this matrix and thereby inhibit tumor growth [36]. Nevertheless, in a randomized trial of PEGPH 20 and modified FOLFIRINOX regimens for metastatic pancreatic cancer, the primary endpoint of early termination of the PEGPH 20 and modified FOLFIRINOX regimens (median OS 7 mo vs 14.4 mo) has not been met [37]. Furthermore, the same occurred in an RCT of PEGPH 20 and GA regimens, with a median OS of 11.2 mo for GA + PEGPH 20 and median OS of 11.6 mo for GA + placebo (HR: 1.0, 95% CI: 0.80-1.27) [27]. Insulin-like growth factor receptor 1 (IGF-1R) is involved in tumor progression of pancreatic cancer and promotes cancer cell growth. Istiratumab, a novel bispecific antibody, enhances drug sensitivity by blocking inhibition of AKT phosphorylation and promoting degradation of IGF-1R and receptor tyrosine protein kinase B3, thereby restoring paclitaxel and gemcitabine activity. In an RCT, ganitumab, an IGF-1R antibody, was added to gemcitabine, resulting in a significant improvement in OS for pancreatic cancer patients [38]. Besides, the trial was terminated early in a subsequent phase III clinical study. In the included trial, GA combined with istiratumab did not show an improvement in OS or shorter PFS in the GA combined...
with istiratumab group, even in the subgroup with high IGF-1R levels. There are many reasons for this result, one of which may be related to the fact that blocking IGF-1R leads to a negative impact on the disease by compensatory signals from other pathways[39]. Cellular autophagy is closely related to the growth of cancer cells, and HCQ plays an effective role in inhibiting autophagy by inhibiting the binding of autophagosomes and lysosomes[40]. In a randomized study of colorectal cancer, the addition of HCQ to a regimen of FOLFOX (oxaliplatin, calcium folinate and fluorouracil) combined with bevacizumab did not significantly improve OS[28]. For this reason, it was expected that the addition of HCQ to GA would not improve OS. A retrospective analysis of the study revealed that the reason for this result may be due to genetic grouping imbalance but in-depth validation of the antitumor effect of HCQ is still needed. Hsp27 inhibits apoptosis by inhibiting caspase protein activity, and several malignancies, including pancreatic cancer, are highly expressed for Hsp27[41]. The activity of aptatorsen alone has been demonstrated[42], and preclinical studies have demonstrated the role of Hsp27 in the treatment of pancreatic cancer[43]. However, in a study that added aptatorsen to GA regimen, the aptatorsen group had even worse performance than the GA group. The above results indicated that any new targeted drug entering the clinic needs more rigorous trials and evaluation.

The mechanism of action of different targeted drugs for cancer treatment has its own complex characteristics. If the GA regimen is combined with drugs with the same target, the results of the systematic analysis will definitely be more objective. However, there are insufficient data from studies on combination of GA with drugs with the same target.

**CONCLUSION**

The GA regimen combined with targeted agents did not have promising results as in preclinical studies. Addition of novel targeted agents did not result in a survival benefit for patients with metastatic pancreatic cancer, and the targeted agents may cause more severe diarrhea. Although the results are not optimistic, we expect more high-level clinical studies to be conducted to improve evaluation of this study.

Although the results of this study were not promising, it is undeniable that for first-line treatment of metastatic pancreatic cancer, the GA regimen has significant antitumor effects and tolerable side effects[44], and is also a safe and effective neoadjuvant treatment option against potentially resectable pancreatic cancer[45]. In the second-line treatment of metastatic pancreatic cancer, the results of a meta-analysis suggested that the use of irinotecan-fluorouracil-folic acid regimen may be beneficial in terms of OS and PFS in patients not previously treated with these agents[46]. In gemcitabine-refractory metastatic pancreatic cancer with an extremely poor prognosis, the combination of nanoliposomal irinotecan with folinic acid is an important option in the second-line treatment of patients with metastatic pancreatic cancer[47]. With more positive results from phase III studies, there are more treatment options available for metastatic pancreatic cancer, and these treatments continue to bring incremental improvements and slowly prolong patient survival[48]. In this challenging field, we have reasons to be optimistic and believe that one day modern medicine can overcome the challenge of metastatic pancreatic cancer.
ARTICLE HIGHLIGHTS

Research background
Pancreatic cancer is a highly malignant disease. Gemcitabine plus albumin combined with nab-paclitaxel (GA) is a common first-line treatment regimen for metastatic pancreatic cancer, and there is currently much clinical controversy about the effectiveness of adding a novel targeted agent to this regimen.

Research motivation
An analysis of studies using GA in combination with targeted drug regimens for the treatment of metastatic pancreatic cancer is presented to discuss its efficacy and safety.

Research objectives
Analysis comparing the effectiveness and safety of GA combined with targeted drug regimens and GA regimens.

Research methods
Eligible randomized controlled trials related to GA and GA + targeted agents were searched in PubMed, EMBASE and Cochrane Library, and overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and toxicity were pooled and finally analyzed by Stata version 15.1. In addition, use Reference Citation Analysis (https://www.referencecitationanalysis.com/) to collect the latest related literature to improve the latest cutting-edge research results.

Research results
There were no significant differences in PFS, OS, and ORR between GA + targeted drugs and GA. Grade 3/4 toxicity, such as fatigue, anemia, vomiting and neutropenia, was not significantly different between the two groups, and the incidence of grade 3/4 diarrhea was significantly increased by GA + targeted agents.

Research conclusions
Adding a novel targeted agent to the GA regimen did not improve survival in patients with metastatic pancreatic cancer.

Research perspectives
There is a gap between clinical and theoretical. Theoretically, new targeted drugs will improve the therapeutic effect but not the same result in the clinic.

FOOTNOTES

Author contributions: Li ZH performed literature search, collected the data, statistical analysis and wrote the manuscript; Ma YJ designed the study, performed literature search, collected the data, performed statistical analysis and wrote the manuscript; Li ZH and Ma YJ have contributed equally to this work; Jia ZH performed statistical analysis, revised the manuscript and provided critical opinion; Weng YY analyzed and interpreted the data; Zhang P, Wang F, and Zhu SJ provided critical opinion and revised the manuscript; Wang F provided critical opinion, participated in literature search, and revised the manuscript; Li ZH and Ma YJ have contributed equally to this work. All authors approved the final manuscript.

Conflict-of-interest statement: The authors declare that there is no potential conflict of interest.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China

ORCID number: Zhong-Hui Li 0000-0003-1442-6769; Fang Wang 0000-0002-6054-2675.

S-Editor: Wang DM
L-Editor: Kerr C
REFERENCES

1. Park W, Chawla A, O'Reilly EM. Pancreatic Cancer: A Review. *JAMA* 2021; 326: 851-862 [PMID: 34547082 DOI: 10.1001/jama.2021.13027]

2. Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated Projection of US Cancer Incidence and Death to 2040. *JAMA Netw Open* 2021; 4: e214708 [PMID: 33825840 DOI: 10.1001/jamanetworkopen.2021.4708]

3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin* 2020; 70: 7-30 [PMID: 31912902 DOI: 10.3322/caac.21590]

4. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res* 2014; 74: 2913-2921 [PMID: 24840647 DOI: 10.1158/0008-5472.CAN-14-0155]

5. Von Hoff DD, Ervin T, Arena FP, Chioarean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris R, Reni M, Dowden S, Lahera D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renshuler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 2013; 369: 1691-1703 [PMID: 24131140 DOI: 10.1056/NEJMoa1304369]

6. Zhang Y, Xu J, Hua I, Liu J, Liang C, Meng Q, Ni Q, Shi S, Yu X. Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis. *J Cancer* 2019; 10: 4420-4429 [PMID: 31413762 DOI: 10.7150/jca.29898]

7. Pusceddu S, Ghidini M, Torchio M, Corti F, Tomasello G, Nger M, Prinzii N, Nichetti F, Cioina A, Di Bartolomeo M, Cabiddu M, Passalacqua R, de Braud F, Petrelli F. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. *Cancers* (Basel) 2019; 11 [PMID: 30959763 DOI: 10.3390/cancers1104084]

8. Li Q, Yuan Z, Yan H, Wen Z, Zhang R, Cao B. Comparison of gemcitabine combined with targeted agent therapy versus gemcitabine monotherapy in the management of advanced pancreatic cancer. *Clin Cancer Res* 2014; 20: 1054-1063 [PMID: 24986485 DOI: 10.1158/0005-8542.CAN-14-0506]

9. Yen WC, Fischer MM, Axelrod F, Bond C, Cain J, Cancilla B, Henner WR, Meisner R, Sato A, Shah J, Tang T, Wallace B, Wang M, Zhang C, Kapoun AM, Lewicki J, Gurney A, Hoey T. Targeting Notch signaling with a Notch2/Notch3 antagonist (taxetumab) inhibits tumor growth and decreases tumor-initiating cell frequency. *Clin Cancer Res* 2015; 21: 2084-2095 [PMID: 25934888 DOI: 10.1158/1078-0432.CCR-14-2808]

10. Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, Gorjestiani S, Li SMA, Truitt M, Olson P, Kim G, Hanahan D, Tempora MA, Sheppard B, Irving B, Chang BY, Varner JA, Coussens LM. Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. *Cancer Discov* 2016; 6: 270-285 [PMID: 26715645 DOI: 10.1158/2159-8290.CD-15-0827]

11. Massó-Valls D, Jauset T, Serrano E, Sohr M, Pedersen K, Affara NI, Whitfield JR, Beaulieu ME, Evan GI, Elias L, Arribas J, Soucek L. Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. *Cancer Res* 2015; 75: 1675-1681 [PMID: 25871847 DOI: 10.1158/0008-5472.CAN-14-2852]

12. Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, Tjulandin SA, Gladkov OA, Holcombe RF, Korn R, Raghuinad N, Dychter S, Jiang P, Shepard HM, Devoe CE. Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. *Clin Cancer Res* 2016; 22: 2848-2854 [PMID: 26813359 DOI: 10.1158/1078-0432.CCR-15-1010]

13. Camblin AJ, Pace EA, Adams S, Curley MD, Rimkus N, Nie L, Wen Z, Zhang R, Cao B. Comparison of gemcitabine combined with targeted agent therapy versus gemcitabine monotherapy in the management of advanced pancreatic cancer. *Clin Cancer Res* 2016; 22: 2848-2854 [PMID: 26813359 DOI: 10.1158/1078-0432.CCR-15-1010]

14. Perera RM, Stoykova S, Nicolay BN, Ross KN, Fitamant J, Boukhali M, Lengrand J, Deshpande V, Selig MK, Ferrone RF, Settleman J, Stephanopoulos G, Dyson NJ, Zoncu R, Ramaswamy S, Has W, Bardeesy N. Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. *Nature* 2015; 524: 361-365 [PMID: 26162480 DOI: 10.1038/nature14587]

15. Yang A, Rajeshkumar NV, Wang X, Yabuuchi S, Alexander BM, Chu GC, Von Hoff DD, Maitra A, Kimmelman AC. Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. *Cancer Discov* 2014; 4: 905-913 [PMID: 24875860 DOI: 10.1158/2159-8290.CD-14-0362]

16. Kamada M, So A, Muramaki M, Rocchi P, Berald F, Gleave M. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. *Mol Cancer Ther* 2007; 6: 299-308 [PMID: 17218637 DOI: 10.1158/1535-7163.MCT-06-0417]

17. SaisiRkkharan S, Shrizer Z, Venkataraman G, Narayanasami U. Roles of heparan-sulfate glycosaminoglycans in cancer. *Nat Rev Cancer* 2002; 2: 521-528 [PMID: 12094238 DOI: 10.1038/nrc482]

18. Franchini M, Mannucci PM. Low-molecular-weight heparins and cancer: focus on antitumoral effect. *Ann Med* 2015; 47: 116-121 [PMID: 25766973 DOI: 10.3109/07853901.2015.1004361]

19. MacDonald A, Priess M, Curran J, Guess J, Farutin V, Oosterom I, Chu CL, Cochran E, Zhang L, Getchell K, Loikema M, Schultes BC, Krause S. Nucparabim, A Multietargeting Heparan Sulfate Motif, Targets Tumor and Stromal Components in Pancreatic Cancer. *Mol Cancer Ther* 2019; 18: 245-256 [PMID: 30401693 DOI: 10.1158/1535-7163.MCT-18-0417]

20. Abu Arab W, Korb R, Sirois M, Rousseau E. Concentration- and time-dependent effects of enoxaparin on human adenocarcinomic epithelial cell line A549 proliferation in vitro. *Can J Physiol Pharmacol* 2011; 89: 705-711 [PMID: 21486255 DOI: 10.1139/y11-060]
21 Fluhr H, Seitz T, Zygmun M. Heparins modulate the IFN-γ-induced production of chemokines in human breast cancer cells. *Breast Cancer Res Treat* 2013; 137: 109-118 [PMID: 23160925 DOI: 10.1007/s10549-012-2334-8]

22 Zhou H, Roy S, Cochran E, Zouaoui R, Chu CL, Duffner J, Zhao G, Smith S, Galcheva-Gargova Z, Karlgren J, Dussault N, Kwan RY, Moy E, Barnes M, Long A, Honan C, Qi YW, Shrivor Z, Ganguly T, Schultes B, Venkataraman G, Kishimoto TK. M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. *PLoS One* 2011; 6: e21106 [PMID: 21698126 DOI: 10.1371/journal.pone.0021106]

23 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* 1996; 17: 1-12 [DOI: 10.1016/0197-2456(95)00134-4]

24 Boston RC, Sumner AE. STATA: a statistical analysis system for examining biomedial data. *Adv Exp Med Biol* 2003; 537: 535-369 [PMID: 14995047 DOI: 10.1007/978-1-4419-9019-8_23]

25 DerSimonian R, Levine RJ. Resolving discrepancies between a meta-analysis and a subsequent large controlled trial. *JAMA* 1999; 282: 664-670 [PMID: 10517720 DOI: 10.1001/jama.282.7.664]

26 Kundra M, Gracian AC, Zafari SF, Meiri E, Bendell J, Algul H, Rivera F, Ahn ER, Watkins D, Pelzer U, Charu V, Zalutsky A, Kuesters G, Pipas JM, Santillana S, Askoxylakis V, Ko AH. Randomized, double-blind, placebo-controlled phase II study of istratumab (MM-141) plus nab-paclitaxel and gemicitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). *Ann Oncol* 2020; 31: 79-87 [PMID: 31912800 DOI: 10.1016/annonc.2019.09.004]

27 Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, Hitre E, Hammel P, Hendiﬁra AE, Bates SE, Li CP, Hingorani SR, de la Foucaudiere C, Kasi A, Heinenmann V, Marayeva Y, Bahary N, Layos L, Sahai V, Zheng L, Lacy J, Park JO, Portales F, Oberstein P, Wu W, Chondros D, Bullock AJ, HALO 109-301 Investigators. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. *J Clin Oncol* 2020; 38: 3158-3194 [PMID: 32706655 DOI: 10.1200/JCO.20.00590]

28 Karacie TB, O’Hara MH, Loaiza-Bonilla A, Reiss KA, Teitelbaum UR, Bocazani E, De Jesus-Acosta A, Reddinginger, Burrell JA, Laheru DA, Von Hoff DD, Amaravadi RK, Dresbin J, O’Dwyer P. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial. *JAMA Oncol* 2019; 5: 993-998 [PMID: 31120501 DOI: 10.1001/jamaoncol.2019.0684]

29 Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodrigueza F, Womack MS 4h, Xiong HQ, Waterhouse DM, Tempero MA, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Ipatinum or Placebo in Patients With Metastatic Pancreatic Cancer: The RAINIER Trial. *Oncologist* 2017; 22: 1427-1429 [PMID: 28935773 DOI: 10.1634/theoncologist.2017-0066]

30 O’Reilly EM, Barone D, Mahalingam D, Bekaii-Saab T, Shao SH, Wolf J, Rosano M, Krause S, Richards DA, Yu KH, Roach JM, Flaherty KT, Ryan DP. Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreatic ductal adenocarcinoma. *Eur J Cancer* 2020; 132: 112-121 [PMID: 32361265 DOI: 10.1016/ijca.2020.03.005]

31 Hu ZI, Bendell JC, Bullock A, LoConte NK, Hatoun H, Rith P, Hool H, Leach JW, Sanchez J, Sohal D, DPs, Strickler J, Patel R, Wang-Gillam A, Firdaus I, Yu KH, Kapoun AM, Holgren E, Zhou L, Dupont J, Picozzi V, Sahai V, O’Reilly EM. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarcevxurab or placebo in patients with untreated metastatic pancreatic cancer. *Cancer Med* 2019; 8: 5148-5157 [PMID: 31347292 DOI: 10.1002/cam4.2425]

32 Tempe M, Oh DY, Tabernero J, Reni M, Van Cutsem E, Hendiﬁra A, Waldschmidt DT, Starling N, Bachet JB, Chang HM, Maurel J, Garcia-Carbonero R, Lonardi S, Coussens LM, Fong L, Tsao LC, Cole G, James D, Macarulla T, Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. *Ann Oncol* 2021; 32: 600-608 [PMID: 33539945 DOI: 10.1016/annonc.2021.01.070]

33 Schwarzbach MA, Witzens-Harig M. Ibrutinib. Recent Results Cancer Res 2014; 289: 257-269 [PMID: 24756799 DOI: 10.1007/978-3-642-45490-3_17]

34 Chanan-Khan A, Cramer P, Demirkarman F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dhilluys MS, Pylvanenho K, Loscertales J, Avigdor A, Rule S, Villa D, Samoiloiva O, Panagiotidou P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salmon M, Sun S, Phelps C, Balasubramanian S, Howes A, Halef M, HELIOS investigators. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. *Lancet Oncol* 2016; 17: 210-211 [PMID: 26655421 DOI: 10.1016/S1470-2045(15)00465-9]

35 Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Gruef T, Friedelberg JW, Rai K, O’Brien S. The Bruton tyrosine kinase inhibitor ibrutinib in patients with chronic lymphocytic leukemia. *Blood* 2015; 125: 2915-2922 [PMID: 25755291 DOI: 10.1182/blood-2014-09-585869]

36 Dong KM, Norton JD, Koverer AL, Hingorani SR, Harris WP. Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20). *Curr Oncol Rep* 2019; 17: 47 [DOI: 10.1007/s11991-017-0608-3]

37 Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Brainch T, Ritch PS, Zalupski MM, Bahary N, Oberstein PE, Wang-Gillam A, Wu W, Chondros D, Jiang P, Kheifisa S, Pu J, Aldrich C, Hendiﬁra AE. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. *J Clin Oncol* 2018; 36: 359-366 [PMID: 29232172 DOI: 10.1200/JCO.2017.74.9554]

38 McCaffery I, Tudor Y, Deng H, Tang R, Suzuki S, Badola S, Kindler HL, Fuchs CS, Loh E, Patterson SD, Chen L, Gansert JL. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and gantitin, an IGFIR inhibitor. *Clin Cancer Res* 2013; 19: 4282-4289 [PMID: 23741071 DOI: 10.1158/1078-0432.CCR-12-1840]

39 Beckwith Y, Yee D. Minireview: Were the IGF Signaling Inhibitors All Bad? *Mol Endocrinol* 2015; 29: 1549-1557
Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. *Nat Rev Cancer* 2017; 17: 528-542 [PMID: 28751651 DOI: 10.1038/nrc.2017.53]

Melle C, Ernst G, Escher N, Hartmann D, Schimmel B, Bleul A, Thieme H, Kaufmann R, Felix K, Friess HM, Settmacher U, Hommann M, Richter KK, Daffner W, Täubig H, Manger T, Claussen U, von Eggeling F. Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker. *Clin Chem* 2007; 53: 629-635 [PMID: 17303689 DOI: 10.1373/clinchem.2006.079194]

Chi KN, Yu EY, Jacobs C, Bazov J, Kollmannsberger C, Higano CS, Mukherjee SD, Gleave ME, Stewart PS, Hotte SJ. A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers. *Ann Oncol* 2016; 27: 1116-1122 [PMID: 27022067 DOI: 10.1093/annonc/mdw068]

Guo Y, Ziesch A, Hocke S, Kampmann E, Ochs S, De Toni EN, Göke B, Gallmeier E. Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S-phase arrest and apoptosis. *J Cell Mol Med* 2015; 19: 340-350 [PMID: 25331547 DOI: 10.1111/jcmm.12444]

Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Tricu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. *J Clin Oncol* 2011; 29: 4548-4554 [PMID: 21969517 DOI: 10.1200/JCO.2011.36.5742]

Ielpo B, Duran H, Diaz E, Fabra I, Caruso R, Ferri V, Malavé L, Hidalgo M, Alvarez R, Plaza C, Quijano Y, Vicente E. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma. *Eur J Surg Oncol* 2016; 42: 1394-1400 [PMID: 26899943 DOI: 10.1016/j.ejso.2016.01.006]

Citterio C, Baccini M, Orlandi E, Di Nunzio C, Cavanna L. Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis. *Oncotarget* 2018; 9: 29801-29809 [PMID: 30038721 DOI: 10.18632/oncotarget.25639]

Passero FC Jr, Grapsa D, Syrigos KN, Saif MW. The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy. *Expert Rev Anticancer Ther* 2016; 16: 697-703 [PMID: 27219482 DOI: 10.1080/14737140.2016.1192471]

Ko AH. Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities. *J Clin Oncol* 2015; 33: 1779-1786 [PMID: 25918299 DOI: 10.1200/JCO.2014.59.7625]
